# A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

> **NCT02514473** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 206 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-809
- **DRUG:** Placebo
- **DRUG:** VX-770

## Key facts

- **NCT ID:** NCT02514473
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2017-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02514473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02514473, "A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02514473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*